Advocacy intelligence hub — real-time data for patient organizations
Krzysztof Bankiewicz — PHASE1
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. — PHASE1, PHASE2
University of Coimbra — NA
University Hospital, Montpellier — NA
Rennes University Hospital — NA
AC Immune SA — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
VYALEV
AbbVie Inc.
VYALEV
(FOSCARBIDOPA/FOSLEVODOPA)standardAbbVie Inc.
12.1 Mechanism of Action VYALEV is a prodrug combination of foscarbidopa (carbidopa-4´-monophosphate) and foslevodopa (levodopa-4´-monophosphate). Fos...
Gocovri
(Amantadine hydrochloride)Orphan drugstandardAdamas Pharmaceuticals, Inc.
Influenza A M2 Protein Inhibitor [EPC]
12.1 Mechanism of Action The mechanism by which amantadine exerts efficacy in the treatment of dyskinesia in patients with Parkinson's disease or as a...
Onapgo
(apomorphine hydrochloride)Orphan drugstandardMDD US Operations, LLC
12.1 Mechanism of Action ONAPGO is a non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D4 receptor, and moderate affi...
Cláudia Ferreira, PhD
CINEICC - Center for Research in Neuropsychology and Cognitive Behavioral Intervention, Faculty of Psychology and Educational Sciences of the University of Coimbra
Inês Matos-Pina, MSc
CINEICC - Center for Research in Neuropsychology and Cognitive Behavioral Intervention, Faculty of Psychology and Educational Sciences of the University of Coimbra
Mariana Moura-Ramos, PhD
Unidade Local de Saúde de Coimbra (ULS Coimbra)
Huw Morris, PhD, FRCP
University College, London
Michael N Sack, M.D., D.C
National Heart, Lung, and Blood Institute (NHLBI)
📍 SPEARFISH, SD
Gian Pal, M.D
Rutgers University
📍 CLIFTON, NJ